Barrington analyst Michael Petusky maintained a Hold rating on Anika Therapeutics (ANIK – Research Report) today. The company’s shares closed yesterday at $25.29.
According to TipRanks, Petusky is a 4-star analyst with an average return of 6.4% and a 50.94% success rate. Petusky covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Merit Medical Systems, and Anika Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Anika Therapeutics with a $28.00 average price target.
See the top stocks recommended by analysts >>
ANIK market cap is currently $372.9M and has a P/E ratio of -24.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
Read More on ANIK:
- Anika Reports First Quarter 2023 Financial Results
- ANIK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
- Anika Enters Into Cooperation Agreement with Caligan Partners
- Anika announces cooperation agreement with Caligan, $20M share repurchase plan
